Association of acute myeloid leukemia's most immature phenotype with risk groups and outcomes

Jonathan M. Gerber,¹ Joshua F. Zeidner,² Sarah Morse,³ Amanda L. Blackford,³ Brandy Perkins, Breann Yanagisawa,³ Hao Zhang,³ Laura Morsberger,³ Judith Karp,³ Yi Ning,³ Christopher D. Gocke,³ Gary L. Rosner,³ B. Douglas Smith,³ and Richard J. Jones³

¹Levine Cancer Institute, Charlotte, NC; ²Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC; and ³The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Johns Hopkins University, Baltimore, MD, USA

©2016 Ferrata Storti Foundation. This is an open-access paper. doi:10.3324/haematol.2015.135194


Received: August 12, 2015.

Accepted: January 22, 2016.


Pre-published: January 27, 2016.

Correspondence: rijones@ihmi.edu


^{*}JMG and JFZ contrbuted equally to this work.



Supplementary Figure 1. Representative CD34 and CD38 staining profiles and gating strategies. A newly diagnosed AML gated for A) CD34 and B) CD38 on the CD34⁺ gated cells. CD38 gating was based on negative antibody control and yielded 9.6% of the CD34⁺ cells.



Supplementary Figure 2A. Diagram of cytogenetic /molecular characteristics for AMLs on clinical trial NCT01349972 with < 1% CD34⁺ cells in the diagnostic bone marrow.



^{*} Other Adverse-risk cytogenetics refers to patients with adverse-risk cytogenetics based on European LeukemiaNet Criteria but without complex karyotype.

Supplementary Figure 2B. Diagram of cytogenetic /molecular characteristics for AMLs on clinical trial NCT01349972 with > 1% CD34+ cells in the diagnostic bone marrow. The ALDHhigh group includes 7 patients with dual ALDHint and ALDHhigh populations.